{"id":"https://openalex.org/W2980077127","doi":"https://doi.org/10.1182/blood.v118.21.3757.3757","title":"A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,","display_name":"A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,","publication_year":2011,"publication_date":"2011-11-18","ids":{"openalex":"https://openalex.org/W2980077127","doi":"https://doi.org/10.1182/blood.v118.21.3757.3757","mag":"2980077127"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v118.21.3757.3757","doi":"https://doi.org/10.1182/blood.v118.21.3757.3757","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v118.21.3757.3757","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076074507","display_name":"Anupriya Agarwal","orcid":"https://orcid.org/0000-0002-8319-6162","observed_orcids":["https://orcid.org/0000-0002-8319-6162"]},"institutions":[{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]},{"id":"https://openalex.org/I4390039369","display_name":"OHSU Knight Cancer Institute","ror":"https://ror.org/002shna07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Anupriya Agarwal","raw_affiliation_strings":["Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA,","institution_ids":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010886409","display_name":"Ryan J. MacKenzie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]},{"id":"https://openalex.org/I4390039369","display_name":"OHSU Knight Cancer Institute","ror":"https://ror.org/002shna07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan MacKenzie","raw_affiliation_strings":["Knight Cancer Institute, Oregon Health & Sciences University, Portland, OR, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Knight Cancer Institute, Oregon Health & Sciences University, Portland, OR, USA,","institution_ids":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017933250","display_name":"Jessica Oddo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126895","display_name":"Oncotide Pharmaceuticals (United States)","ror":"https://ror.org/030xyk527","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126895"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica Oddo","raw_affiliation_strings":["Research, Oncotide Pharmaceuticals, Durham, NC, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research, Oncotide Pharmaceuticals, Durham, NC, USA,","institution_ids":["https://openalex.org/I4210126895"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000594249","display_name":"Michael Peter Vitek","orcid":"https://orcid.org/0000-0001-8140-8048","observed_orcids":["https://orcid.org/0000-0001-8140-8048"]},"institutions":[{"id":"https://openalex.org/I4210126895","display_name":"Oncotide Pharmaceuticals (United States)","ror":"https://ror.org/030xyk527","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126895"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Michael P Vitek","raw_affiliation_strings":["Research, Oncotide Pharmaceuticals, Durham, NC, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research, Oncotide Pharmaceuticals, Durham, NC, USA,","institution_ids":["https://openalex.org/I4210126895"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111673693","display_name":"Dale J. Christensen","orcid":"https://orcid.org/0009-0007-6013-0770","observed_orcids":["https://orcid.org/0009-0007-6013-0770","https://orcid.org/0000-0003-3815-6839"]},"institutions":[{"id":"https://openalex.org/I4210126895","display_name":"Oncotide Pharmaceuticals (United States)","ror":"https://ror.org/030xyk527","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126895"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dale J. Christensen","raw_affiliation_strings":["R & D, Oncotide Pharmaceuticals, Research Triangle Park, NC, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"R & D, Oncotide Pharmaceuticals, Research Triangle Park, NC, USA,","institution_ids":["https://openalex.org/I4210126895"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5125591963","display_name":"Brian J. Druker","orcid":"https://orcid.org/0000-0001-8331-8206","observed_orcids":["https://orcid.org/0000-0001-8331-8206"]},"institutions":[{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]},{"id":"https://openalex.org/I4390039369","display_name":"OHSU Knight Cancer Institute","ror":"https://ror.org/002shna07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian J. Druker","raw_affiliation_strings":["Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA","institution_ids":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5000594249","https://openalex.org/A5076074507"],"corresponding_institution_ids":["https://openalex.org/I165690674","https://openalex.org/I4210126895","https://openalex.org/I4390039369"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":1.514,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.84322074,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"118","issue":"21","first_page":"3757","last_page":"3757"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9259999990463257},{"id":"https://openalex.org/keywords/pp2a-activation","display_name":"PP2A activation","score":0.8679999709129333},{"id":"https://openalex.org/keywords/bcr-abl","display_name":"BCR-ABL","score":0.777999997138977},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.871999979019165},{"id":"https://openalex.org/keywords/t315i-mutation","display_name":"T315I mutation","score":0.8799999952316284},{"id":"https://openalex.org/keywords/abl-tyrosine-kinase-inhibitors","display_name":"ABL tyrosine kinase inhibitors","score":0.9160000085830688},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7609999775886536},{"id":"https://openalex.org/keywords/cell-penetrating-peptides","display_name":"cell-penetrating peptides","score":0.8309999704360962},{"id":"https://openalex.org/keywords/fingolimod","display_name":"fingolimod","score":0.7940000295639038},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.6930000185966492},{"id":"https://openalex.org/keywords/k562-cells","display_name":"K562 cells","score":0.6949999928474426},{"id":"https://openalex.org/keywords/blast-crisis","display_name":"blast crisis","score":0.39100000262260437}],"concepts":[{"id":"https://openalex.org/C389152","wikidata":"https://www.wikidata.org/wiki/Q6593007","display_name":"Protein phosphatase 2","level":4,"score":0.713599681854248},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6269326210021973},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5551801919937134},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.5476663112640381},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.5028650164604187},{"id":"https://openalex.org/C125418893","wikidata":"https://www.wikidata.org/wiki/Q587961","display_name":"ABL","level":4,"score":0.4957226514816284},{"id":"https://openalex.org/C171122931","wikidata":"https://www.wikidata.org/wiki/Q6324626","display_name":"K562 cells","level":3,"score":0.48172643780708313},{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.4816652536392212},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.45320773124694824},{"id":"https://openalex.org/C2780381907","wikidata":"https://www.wikidata.org/wiki/Q198728","display_name":"Ponatinib","level":5,"score":0.44342225790023804},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.4308116137981415},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.42202723026275635},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4211728274822235},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.2872864305973053},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.28221395611763},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.24957886338233948},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.23383888602256775},{"id":"https://openalex.org/C178666793","wikidata":"https://www.wikidata.org/wiki/Q422476","display_name":"Phosphatase","level":3,"score":0.18045535683631897},{"id":"https://openalex.org/C11960822","wikidata":"https://www.wikidata.org/wiki/Q242736","display_name":"Phosphorylation","level":2,"score":0.17141050100326538}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v118.21.3757.3757","doi":"https://doi.org/10.1182/blood.v118.21.3757.3757","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v118.21.3757.3757","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2114625809","https://openalex.org/W2199691549","https://openalex.org/W1534139344","https://openalex.org/W2148763134","https://openalex.org/W3037965257","https://openalex.org/W3135833462","https://openalex.org/W7099959780","https://openalex.org/W2055049504","https://openalex.org/W2970987045","https://openalex.org/W2580147791"],"abstract_inverted_index":{"Abstract":[0,1],"3757":[2],"Background:":[3],"The":[4],"majority":[5],"of":[6,26,48,58,66,92,109,119,123,134,147,157,187,193,280,313,389,395,423,450,460,470,489,506,518,554,570,627,633,736,747],"patients":[7,28,162,635],"with":[8,16,113,163,214,248,277,297,369,397,427,440,454,465,533,557,572,636,646,669,692],"chronic":[9],"myeloid":[10],"leukemia":[11,577],"(CML)":[12],"achieve":[13],"durable":[14],"remissions":[15],"ABL":[17,32,127,398,455,639,647],"tyrosine":[18],"kinase":[19,39],"inhibitor":[20,72],"(TKI)":[21],"therapy.":[22],"However,":[23],"a":[24,151,170,205,283,300,527,545,623,718],"subset":[25],"CML":[27,61,103,120,158,201,291,338,355,420,498,547,595,629,634],"develop":[29],"resistance":[30,637],"to":[31,126,154,181,219,239,259,329,343,524,581,594,638,673,696,731],"TKIs,":[33],"either":[34,641],"through":[35,88],"BCR-ABL":[36,44,59,100,139],"kinase-dependent":[37,140],"(e.g.":[38,46],"domain":[40],"point":[41],"mutations)":[42],"or":[43,115,404,643],"kinase-independent":[45,142],"overexpression":[47,65],"LYN)":[49],"mechanisms.":[50],"Recent":[51],"studies":[52,192,512],"have":[53,717],"demonstrated":[54],"that":[55,179,304,589],"the":[56,67,131,155,228,278,310,393,447,458,744],"presence":[57],"in":[60,64,75,84,102,136,190,195,209,235,252,261,290,353,382,413,417,452,496,509,520,598,601,644,721,725,749],"cells":[62,106,292,320,332,339,349,386,415,421,499,502,596],"result":[63],"protein":[68,462],"phosphatase":[69],"2A":[70],"(PP2A)":[71],"SET,":[73],"which":[74,435],"turn":[76],"prevents":[77],"PP2A":[78,93,110,135,148,210,229,236,284,301,473,608],"from":[79],"performing":[80],"its":[81,286],"regulatory":[82],"role":[83,133,279],"deactivating":[85],"signaling":[86],"proteins":[87],"dephosphorylation.":[89],"Further,":[90],"loss":[91],"function":[94],"accounts":[95],"for":[96,161,318,625,631,675,698],"increased":[97,256,411],"and":[98,107,141,183,198,255,268,367,372,410,416,484,487,494,500,563,600,606,671,679,683,694,702,706,714,741],"sustained":[99],"activity":[101,211,237],"blast":[104],"crisis":[105],"activation":[108,146],"via":[111],"treatment":[112,213,247,296,439,569,632],"Forskolin":[114],"FTY720":[116,231,260],"reduces":[117],"clonogenicity":[118],"cells,":[121,357],"regardless":[122],"their":[124],"sensitivity":[125],"TKIs.":[128,456,648],"Therefore,":[129],"given":[130],"central":[132],"regulating":[137],"both":[138,597],"downstream":[143,482],"signaling,":[144,483],"pharmacological":[145],"may":[149],"provide":[150],"novel":[152],"approach":[153],"development":[156,626],"therapeutics,":[159],"particularly":[160],"imatinib-resistant":[164],"CML.":[165],"Results:":[166],"Here,":[167],"we":[168,358],"report":[169],"novel,":[171],"specific,":[172],"cell":[173,202],"penetrating":[174],"peptide":[175],"known":[176],"as":[177,282,579,622],"OP449":[178,194,216,223,249,281,305,314,344,396,426,451,466,478,519,534,555,571,590],"binds":[180],"SET":[182,461,605,620],"antagonizes":[184],"SET's":[185],"inhibition":[186],"PP2A.":[188,308],"Initial":[189],"vitro":[191,599],"human":[196,384],"(K562)":[197],"murine":[199,546],"(32Dp210)":[200],"lines":[203],"revealed":[204],"robust":[206],"(45%)":[207],"increase":[208,234],"after":[212],"1\u03bcM":[215],"when":[217],"compared":[218,238,258,580],"vehicle":[220,240],"treated":[221,241,532],"cells.":[222,275,567],"was":[224,363,380,436],"more":[225,316,437],"potent":[226],"than":[227,438,540],"activator":[230],"(5\u03bcM;":[232],"20%":[233],"control).":[242],"In":[243,526,544],"comparative":[244],"cytotoxicity":[245],"studies,":[246],"consistently":[250],"resulted":[251],"reduced":[253,364,408,430,476,560,564,576],"proliferation":[254,409],"apoptosis":[257,412],"K562":[262,414,501],"(IC50:":[263,270,333],"2.5\u03bcM":[264],"vs.":[265,272],"5\u03bcM,":[266],"respectively)":[267,274],"LAMA":[269],"1.25\u03bcM":[271],"2.5\u03bcM,":[273],"Consistent":[276],"activator,":[285],"growth":[287],"inhibitory":[288],"effects":[289,312],"were":[293,340,475],"rescued":[294],"by":[295,365,433,603,743],"okadaic":[298],"acid,":[299],"inhibitor,":[302,474],"indicating":[303],"specifically":[306],"activates":[307],"Furthermore,":[309,616],"cytotoxic":[311,593],"are":[315],"selective":[317],"BCR-ABL-positive":[319],"(K562,":[321],"LAMA,":[322],"32Dp210":[323,528],"IC50":[324],"range:":[325],"1.0":[326],"\u20132.5\u03bcM)":[327],"relative":[328],"parental":[330],"32D":[331],"5\u03bcM).":[334],"Importantly,":[335],"TKI-resistant":[336],"mutant":[337],"also":[341,479],"sensitive":[342],"at":[345,387],"similar":[346],"doses":[347,553],"(32Dp210T315I":[348],"IC50:":[350],"2.5\u03bcM).":[351],"Similarly,":[352],"primary":[354,418],"CD34+":[356,385,419,497],"noted":[359],"CFU-GM":[360],"colony":[361,431],"formation":[362,432],"75%":[366],"98%":[368],"2.5":[370,424],"\u03bcM":[371,374,425],"5":[373,390],"OP449,":[375],"respectively,":[376],"while":[377],"no":[378],"toxicity":[379,511,517],"observed":[381],"normal":[383],"concentration":[388],"\u03bcM.":[391],"Intriguingly,":[392],"combination":[394,422,453,645],"TKIs":[399,640],"(imatinib":[400],"1.0\u03bcM,":[401],"nilotinib":[402,428,573],"50nM,":[403],"dasatinib":[405],"5nM)":[406],"further":[407,575],"(50nM)":[429],"98%,":[434],"each":[441],"drug":[442],"alone.":[443],"These":[444],"data":[445,587,618,680,703],"support":[446],"potential":[448,734],"use":[449],"Mechanistically,":[457],"amount":[459],"remained":[463],"unchanged":[464],"treatment,":[467],"although":[468],"levels":[469],"CIP2a,":[471],"another":[472],"significantly.":[477],"inhibited":[480],"BCR-ABL-mediated":[481],"induced":[485],"dephosphorylation":[486],"degradation":[488],"BCR-ABL,":[490],"STAT5,":[491],"AKT,":[492],"ERK,":[493],"p38/MAPK":[495],"within":[503],"6":[504],"hr":[505],"treatment.":[507],"Lastly,":[508],"vivo":[510,602],"did":[513],"not":[514],"identify":[515],"any":[516],"non-leukemic":[521],"mice":[522,531,542],"up":[523],"10mg/kg/day.":[525],"xenograft":[529],"model,":[530,551],"survived":[535],"slightly":[536],"but":[537],"significantly":[538],"longer":[539],"vehicle-treated":[541],"(p=0.05).":[543],"bone":[548],"marrow":[549],"transplantation":[550],"increasing":[552,607],"correlated":[556],"improved":[558],"survival,":[559],"WBC":[561],"count,":[562],"GFP+":[565],"leukemic":[566],"Combination":[568],"showed":[574],"burden":[578],"monotherapy.":[582],"Conclusions:":[583],"Taken":[584],"together,":[585],"these":[586,617],"demonstrate":[588],"is":[591],"selectively":[592],"antagonizing":[604],"activity,":[609],"thus":[610],"restoring":[611],"PP2A's":[612],"tumor":[613],"suppressor":[614],"function.":[615],"validate":[619],"antagonism":[621],"target":[624],"new":[628],"therapeutics":[630],"alone":[642],"Disclosures:":[649],"Oddo:":[650],"Oncotide:":[651],"Employment,":[652,656,660],"Research":[653,750],"Funding.":[654],"Vitek:Oncotide:":[655],"Equity":[657,661,710],"Ownership.":[658,662],"Christensen:Oncotide:":[659],"Druker:Bristol-Myers-Squibb:":[663],"OHSU":[664,687,713,745],"has":[665,688,728,738],"clinical":[666,689],"trial":[667,690],"contracts":[668,691],"Novartis":[670,693],"Bristol-Myers-Squibb":[672,695],"pay":[674,697],"patient":[676,699],"costs,":[677,700],"nurse":[678,701],"manager":[681,704],"salaries,":[682,705],"institutional":[684,707],"overhead.;":[685,708],"Novartis:":[686],"MolecularMD:":[709],"Ownership,":[711],"verbatim:":[712],"Dr.":[715],"Druker":[716],"financial":[719],"interest":[720,737],"MolecularMD.":[722,732],"Technology":[723],"used":[724],"this":[726],"research":[727],"been":[729,739],"licensed":[730],"This":[733],"conflict":[735],"reviewed":[740],"managed":[742],"Conflict":[746],"Interest":[748],"Commi;":[751],"Cylene:":[752],"Consultancy;":[753],"Ariad":[754],"pharmaceuticals:":[755],"Consultancy.":[756]},"counts_by_year":[{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2019-10-18T00:00:00"}